Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure

Circulation

Volumn 101, Issue 6, 2000, Pages 594-597

  Farquharson, Colin A J ^a   Struthers, Allan D ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Angiotensin; Endothelium; Enzymes; Heart failure; Nitric oxide; Spironolactone

Indexed keywords

ACETYLCHOLINE; ANGIOTENSIN; ANGIOTENSIN I; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; N(G) METHYLARGININE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PLACEBO; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIURETIC THERAPY; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; FOREARM BLOOD FLOW; HEART FAILURE; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VASCULAR ENDOTHELIUM; VASODILATATION; VEIN OCCLUSION PLETHYSMOGRAPHY;

EID: 0034651798     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.101.6.594     Document Type: Article

References (13)

1. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J, for the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709-717.
2. Struthers AD. Why does spironolactone improve mortality over and above an ACE-inhibitor in chronic heart failure? Br J Clin Pharmacol. 1999;47:479-482.
3. Ikeda U, Kanbe T, Nakayama I, Kawahara Y, Yokoyama M, Shimada K. Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1β. Eur J Pharmacol. 1995;290:69-73.
4. Sun Y, Ratajska A, Zhou G, Weber KT. Angiotensin convening enzyme and myocardial fibrosis in the rat receiving angiotensin II or aldosterone. J Lab Clin Med. 1993;122:395-403.
5. Sun Y, Weber KT. Angiotensin II and aldosterone receptor binding in rat heart and kidney: response to chronic angiotensin II or aldosterone administration. J Lab Clin Med. 1993;122:404-411.
6. Ullian ME, Schelling JR, Linas SL. Aldosterone enhances angiotensin II receptor binding and inositol phosphate responses. Hypertension. 1992; 20:67-73.
7. Benjamin N, Calver A, Collier J, Robinson B, Vallance P, Webb DJ. Measuring forearm blood How and interpreting the responses to drugs and mediators. Hypertension. 1995;25:918-923.
8. Davidson NC, Barr CS, Struthers AD. C-type natriuretic peptide: an endogenous inhibitor of vascular angiotensin-converting enzyme activity. Circulation. 1996;93:1155-1159.
9. Duprez DA, DeBuyzere ML, Rietzschel ER, Taes Y, Clement DL, Morgan D, Cohn JN. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J. 1998;19:1371-1376.
10. Davidson NC, Struthers AD. Nitric oxide regulates renin release during salt depiction but does not alter angiotensin responses in normal humans. J Cardiovasc Pharmacol Ther. 1999;4:9-14.
11. 2 generation by low-dose aspirin at the site of plug formation in man in vivo. Circulation. 1987;75:1025-1029.
12. + is an endothelium-derived hyperpolarising factor in rat arteries. Nature. 1998; 396:269-272.
13. Drexler H. Endothelium as a therapeutic target in heart failure. Circulation. 1998;98:2652-2655.